Rapid eye movement sleep, apnea, and cardiac slowing influenced by phenobarbital administration in the neonate

Pediatrics
|October 1, 1977
PubMed

Insights

Phenobarbital (phenobarbitone) reduced active sleep and neurogenic apnea/bradycardia in preterm infants. As drug levels decreased, these symptoms returned, supporting a neurophysiologic link between active sleep and apnea.

Area of Science:

  • Neonatal Medicine
  • Neurophysiology
  • Pharmacology

Background:

  • Neonatal apnea and bradycardia are significant concerns in preterm infants.
  • The neurophysiological mechanisms underlying these events are not fully understood.
  • Phenobarbital is a commonly used medication in neonatal care.

Purpose of the Study:

  • To evaluate the effect of phenobarbital on neonatal sleep behavior.
  • To assess the impact of phenobarbital on the incidence of neurogenic apnea and/or bradycardia.
  • To investigate the relationship between phenobarbital serum levels, active sleep, and apnea/bradycardia.

Main Methods:

  • Polygraphic recordings were conducted in seven preterm infants.
  • Infants received phenobarbital to achieve therapeutic serum levels.
  • Sleep patterns and the occurrence of apnea/bradycardia were monitored.

Main Results:

  • Therapeutic phenobarbital levels decreased active sleep and the incidence of apnea/bradycardia.
  • Apnea and bradycardia predominantly occurred during active sleep.
  • As phenobarbital levels declined, active sleep rebounded, and apnea/bradycardia recurred.

Conclusions:

  • Phenobarbital effectively reduces active sleep and associated apnea/bradycardia in preterm infants.
  • The findings support the hypothesis that active sleep facilitates neonatal apnea.
  • Active sleep-inhibitory brain mechanisms may play a role in the pathophysiology of neonatal apnea.

Related Concept Videos

CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
States of Arousal During Infancy01:30

States of Arousal During Infancy

States of arousal describe an infant’s physiological and behavioral condition during sleep, wakefulness, and activity. These states are regulated by the circadian rhythm, an internal biological clock that organizes daily patterns of rest and alertness. During infancy, arousal is commonly classified into five states: regular sleep, irregular sleep, drowsiness, alert inactivity, and waking activity.Regular and Irregular SleepDuring regular sleep, an infant’s eyes remain closed, breathing is slow...